Kconcept / Shutterstock.com
The US Court of Appeals for the Federal Circuit’s affirmation of the Patent Trial and Appeal Board’s (PTAB) decision to invalidate a Merck patent used to reduce homocysteine in the human body faced criticism from a dissenting judge, who claimed the court showed too much deference to the body’s decision.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
CAFC; PTAB; USPTO; Merck; Gnosis; America Invents Act